Ovasave

TxCell · discontinued Small molecule

At a glance

Generic name	Ovasave
Sponsor	TxCell
Modality	Small molecule
Therapeutic area	Other
Phase	discontinued

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase IIb, Multicentre, Randomised, Double-blinded, Placebo-controlled, Multi-dose and Multi-injection, Parallel Groups Study to Evaluate the Efficacy and the Safety of Ovasave in Patients With Acti (Phase 2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ovasave CI brief — competitive landscape report
Ovasave updates RSS · CI watch RSS
TxCell portfolio CI